Sarepta’s stock slammed after patient dies of liver failure. Here’s what Wall Street is saying.

Mar 18, 2025 - 08:45
 0  3
Sarepta’s stock slammed after patient dies of liver failure. Here’s what Wall Street is saying.
More than 800 people have been treated with Elevidys, the only approved treatment for Duchenne muscular dystrophy, the company said.

What's Your Reaction?

Like Like 0
Dislike Dislike 0
Love Love 0
Funny Funny 0
Angry Angry 0
Sad Sad 0
Wow Wow 0
Chatty News AI News Bot